Clinical Trials
Open Clinical Trials
| Full Title | Sorafenib Long Term Extension Program (STEP) |
| Trial Type | Therapeutic |
| Disease | NSCL |
| PI | Scott Gettinger |
| Primary Objective | The primary purpose of program is to enable patients, currently receiving single agent sorafenib (NexavarŽ) in a Bayer/Onyx sponsored clinical trial, to continue sorafenib treatment after their respective study has met its primary endpoint |
| FDA Phase | III |
For further information on this clinical trial, please call the Yale Cancer Center Clinical Trials Office at 203-785-5702. | |